Physician profile
Hemant Patel
NPI 1679924955
$10,658.17
in general payments reported to CMS, 2019-2025
36 companies · $3,262 in 2025
The $3,262 reported for 2025 was more than what 90% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $609 · 2021: $2,724 · 2022: $1,657 · 2023: $517 · 2024: $1,152 · 2025: $3,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,726 · Food and Beverage: $2,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,726.02 |
| Food and Beverage | $2,204.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle, INC | $5,566.93 | 2019-2025 | |
| Arthrex, INC. | $1,462.10 | 2025 | |
| Stryker Corporation | $1,138.96 | 2019-2025 | Easyfuse, Prostep, Ortholoc 3di Crosscheck |
| Medical Device Business Services, INC. | $687.23 | 2024 | |
| Depuy Synthes Sales INC. | $254.89 | 2019-2024 | Na, Motoband |
| Medtronic, INC. | $254.49 | 2022-2025 | Venaseal, Intellis Adaptivestim |
| Anika Therapeutics, INC. | $175.83 | 2021-2023 | Tactoset, Toe Motion |
| Zimmer Biomet Holdings, INC. | $138.62 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $119.05 | 2020-2022 | |
| Smith+Nephew, INC. | $82.84 | 2019-2021 | |
| Orthofix Medical, INC. | $62.90 | 2019-2025 | Physio-Stim |
| Inari Medical, INC. | $57.61 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Paragon 28, INC. | $56.92 | 2019-2023 | Additive Orthopedics |
| Philips North America LLC | $55.22 | 2019 | |
| Horizon Therapeutics Plc | $52.54 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $48.51 | 2022-2025 | Puraply Wound Matrix |
| Averitas Pharma INC. | $41.15 | 2023 | Qutenza |
| Integra Lifesciences Corporation | $34.80 | 2022 | |
| Ossio INC | $29.93 | 2021 | |
| Kci USA, INC. | $29.11 | 2023 | V.A.C. Veraflo, V.A.C.Ulta, Prevena |
| Pfizer INC. | $27.40 | 2019-2020 | |
| Kerecis Limited | $24.74 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Cardiovascular Systems INC. | $24.62 | 2019 | |
| Nabriva Therapeutics, Plc | $23.76 | 2022 | |
| Abbott Laboratories | $22.90 | 2023 | Proclaim |
| Convatec INC. | $21.24 | 2022 | |
| Heron Therapeutics, INC. | $20.85 | 2024 | Zynrelef |
| Sun Pharmaceutical Industries INC. | $19.63 | 2019 | |
| Almirall LLC | $19.35 | 2019 | |
| Amgen INC. | $18.02 | 2024 | Krystexxa |
| Axogen | $16.29 | 2021 | |
| Osteomed LLC | $15.49 | 2021 | |
| Merck Sharp & Dohme LLC | $14.65 | 2019 | |
| Next Science LLC | $14.18 | 2023 | Xperience, Surgx, Blastx |
| Paratek Pharmaceuticals, INC. | $12.74 | 2021 | |
| Grt US Holding, INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemant Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.